News: Daiichi Sankyo Co Ltd (4568.T)
4568.T on Tokyo Stock Exchange
1,876JPY
10:07pm EDT
1,876JPY
10:07pm EDT
Price Change (% chg)
¥64 (+3.53%)
¥64 (+3.53%)
Prev Close
¥1,965
¥1,965
Open
¥1,852
¥1,852
Day's High
¥1,899
¥1,899
Day's Low
¥1,821
¥1,821
Volume
1,833,400
1,833,400
Avg. Vol
2,939,973
2,939,973
52-wk High
¥2,014
¥2,014
52-wk Low
¥1,168
¥1,168
Select another date:
Ranbaxy slumps after Daiichi Sankyo says was misled
MUMBAI - Shares in Ranbaxy Laboratories Ltd fell as much as 10.7 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believed former shareholders of the Indian company hid information regarding U.S. regulatory probes.
UPDATE 1-Ranbaxy slumps after Daiichi Sankyo says was misled
(Adds response from Singh family, details; updates share price)
ArQule, Daiichi's colorectal cancer drug fails trial
- An experimental colorectal cancer drug being developed by ArQule Inc and Japan's Daiichi Sankyo Co Ltd failed to improve patient survival without the cancer worsening, in a mid-stage trial, sending ArQule's shares down 18 percent.
UPDATE 2-ArQule, Daiichi's colorectal cancer drug fails trial
* Drug failed to meet goal of improving survival without the cancer growing
Select another date:
Press Releases
- New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Presented at TCT
- Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure
- Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates

